Three recent studies involving 190 [33], 68 [59] and 186 [60] NSCLC patients suggest that HER2 overexpression is not associated with the objective response to chemoradiotherapy, i.e., is not predictive of response to chemotherapy or survival (gefitinib [33], 5-fluorouracil/cisplatin/hyperfractionated RT and docetaxel/cisplatin/RT [59] and cisplatin/vinblastine, followed by RT, with or without concurrent chemotherapy with carboplatin [60]). This evidence concerns the gene ERBB2 and non-small cell lung carcinoma.